Pfizer's Pfourteenth Settlement - a Small Reminder of Continuing Impunity
Well, that did not take long. Less than a month after its last legal settlements were announced, Pfizer had to settle again. The Details of the Settlement This case, involving charges filed by the Texas Attorney General, was only reported locally, e.g., here in the Houston Business Journal:The state of Texas will receive more than $36 million from two civil Medicaid fraud settlements with Pfizer Inc and Endo Pharmaceuticals, Attorney General Greg Abbott said Friday. Both companies will pay $18.17 million to the state, plus attorney fees and relator shares. The federal government is also entitled to a share of the total settlement, Abbott’s statement said.As usual, the settlement was about deceptions: State and federal law requires drug companies disclose to the Medicaid program the prices they charge pharmacies, wholesalers and distributors for their products. Texas’ lawsuits claimed the companies misreported the price of various generic drugs and overcharged Medicaid for certain products.As usual, Pfizer had excuses: In the Pfizer settlement, the state’s investigation originally targeted entities that are now wholly owned subsidiaries of Pfizer.In making the settlements, neither company is admitting to any wrongdoing.New York-based Pfizer released a statement saying the safety of its subsidiaries’ products was not an issue of the investigation and Pfizer was not a target or subject of the case. 'Pfizer’s subsidiaries ...
In conclusion, the findings of the present study indicated that DHA may significantly decrease the serum TG levels and alter the gut microbiota, which suggested its potential to be used for the treatment of hyperlipidemia, inflammatory and neurodegenerative disorders. PMID: 32468008 [PubMed - as supplied by publisher]
Publication date: Available online 29 May 2020Source: SeizureAuthor(s): Monika Mochol, Erik Taubøll, Pål Aukrust, Thor Ueland, Ole A. Andreassen, Sigrid Svalheim
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Isabelle Sylvén, Ingrid Olsson, Tove Hallböök, Bertil Rydenhag, Colin Reilly
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Yan Jiang, Yi Yang, Fei Feng, Ying Zhang, Xiao-Hang Wang, Fei-Lin Ni, Qun Hou, Li-Ping Zhang
Publication date: Available online 30 May 2020Source: Epilepsy &BehaviorAuthor(s): Naoto Kuroda
CONCLUSION: Almost all patients' clinical features were associated with 18q- syndrome. There are very few reported cases with similar genotype possibly caused by a de novo unequal recombination mechanism. PMID: 32468472 [PubMed - in process]
Authors: Kalli E Abstract Lipids constitute almost 60% of the brain's dry weight, and they are thought to be involved in inflammation, neurotransmission and synaptic plasticity. The brain mostly contains sphingolipids, glycerophospholipids and cholesterol which are abundant in myelin and neuronal membranes. The recent rise of the promising area of lipidomic data can be used as a diagnosing tool at the early stages of Alzheimer's disease allowing novel therapeutic targets. In this review, altered lipid metabolites as well as the impact of diet in the progress of Alzheimer's disease (AD) are analyzed. PMID: 32468...
Publication date: Available online 29 May 2020Source: Journal of Chemical NeuroanatomyAuthor(s): Ola Mohammed Youssef, Amira Ibrahim Morsy, Mona A. El-Shahat, Amany M Shams, Samira Lotfy Abd-Elhady
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
AbstractEffects of statins over clinical changes in Alzheimer ’s disease (AD) are usually non-significant, but epistatic interactions between genetic variants involved in cholesterol metabolism could be important for such effects. We aimed to investigate whetherLDLR single-nucleotide polymorphisms rs11669576 (LDLR8), rs5930 (LDLR10), and rs5925 (LDLR13) are associated with cognitive and functional changes in AD, while also consideringAPOE haplotypes and lipid-lowering treatment with lipophilic statins for stratification. Consecutive outpatients with late-onset AD were screened with cognitive tests, while caregivers s...
More News: Academia | Appendicitis | Asbestosis | Atorvastatin Calcium | Cholesterol | Detrol | Epilepsy | Gabapentin | Genetics | Government | Harvard | Health | Health Management | Health Medicine & Bioethics Commentators | Hormones | Hospital Management | Hospitals | Internal Medicine | Lawsuits | Legislation | Linezolid | Lipitor | Lyrica | Marketing | Medicaid | Medical Ethics | Men | Neurology | Neurontin | Pantoprazole | Pfizer | Proton Pump Inhibitors PPIs | Protonix | Recession | Statin Therapy | Texas University | Zivast | Zyvox